Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2021
CSRC Warns Lepu Medical and Chairman Pu Zhongjie
In September 2021, regulators issued warning letters to Lepu Medical and chairman Pu Zhongjie over issues including fulfillment of commitments; Pu's earlier remarks that 'medicine is too cheap, so consumers dare not buy it' had also sparked controversy. The company received the warning letter; its market value had evaporated by about RMB 60 billion from its peak.
2018
Lepu Medical Penalized for Commercial Bribery
In 2018, media reported that an entity under Lepu Medical was administratively penalized for commercial bribery; at the same time, the company's annual meeting expenses exceeded RMB 60 million, raising questions about hidden compliance risks in sales expenses. The relevant subsidiary was fined and had illegal gains confiscated, drawing attention to marketing compliance in the medical device industry.